An article written by Cynthia Mazareas and Craig Hilts, published by Xconomy on February 28, 2019. The article provides a recap of the 2018 market for early-stage public biotech companies, a peek into 2019 conditions, and goes on to outline how early-stage public companies can position themselves to maximize and maintain investor engagement and to execute financings from a position of strength.
Excerpt: Last year was a remarkable year for biotech companies going public. Not only did an unusually large number of biotech companies go public, but a significant number of early-stage biotech companies went public at premium valuations relative to their later-clinical stage peers. Read the full article.
